Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis

Leuk Res. 2011 Jan;35(1):44-8. doi: 10.1016/j.leukres.2010.04.015. Epub 2010 May 21.


We assessed plasma cell proliferation (by propidium iodide index, PC-PI) and apoptosis (by annexin-V index PC-AI) for the estimation of overall survival (OS) in multiple myeloma (MM) patients. 181 patients with newly diagnosed MM were assessed, treated using conventional chemotherapy. The values best discriminating patients with poor prognosis were PC-PI>3.0% and PC-AI<4.75%, and for good prognosis PC-PI≤3.0% and PC-AI≥4.75%. The median OS was 8 months vs 40 months, p=0.0002. Our results suggest that combined measurement of plasma cell proliferation and apoptosis creates a unique strong prognostic factor based on growth characteristics of the tumor clone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Apoptosis*
  • Cell Proliferation*
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology*
  • Plasma Cells / cytology*
  • Prognosis
  • Survival Analysis


  • Antineoplastic Agents